LB Pharmaceuticals grants equity award to new General Counsel Dr. Minako Pazdera as part of her employment agreement.
Quiver AI Summary
LB Pharmaceuticals Inc announced the granting of an equity award to Dr. Minako Pazdera, its new General Counsel, as part of her employment inducement. The award consists of options to purchase 140,000 shares of the company’s common stock, with an exercise price of $24.22. The options vest over four years, starting with 25% vesting after one year. Additionally, LB Pharmaceuticals is focused on developing LB-102, a novel investigational antipsychotic aimed at treating neuropsychiatric disorders, with ongoing clinical trials for conditions such as bipolar depression and schizophrenia. The company believes LB-102 could become a significant treatment option in psychiatry, addressing key limitations of existing therapies.
Potential Positives
- LB Pharmaceuticals appointed Dr. Minako Pazdera as General Counsel, indicating a strengthening of its leadership team.
- Dr. Pazdera received a significant equity award, reflecting the company's commitment to attracting top talent through competitive compensation packages.
- The company is advancing its lead candidate, LB-102, with ongoing Phase 2 trials and plans for Phase 3 trials, showcasing its progress in developing treatments for serious neuropsychiatric disorders.
- LB-102 has the potential to be the first benzamide antipsychotic approved in the U.S., which could position the company favorably within the pharmaceutical market.
Potential Negatives
- Granting a significant equity award to a new General Counsel could raise concerns about executive compensation in a company that may be perceived as financially unstable or struggling, particularly if the company has not yet established a strong commercial presence with its lead product, LB-102.
- The reliance on an "inducement grant" structure may signal to investors that the company is facing challenges in attracting talent, which could reflect negatively on its operational stability and attractiveness as an employer.
- The timeline for clinical trials, with a Phase 3 trial for LB-102 expected to commence in 1Q 2026 and a Phase 2 trial not starting until 2027, may indicate a slow pathway to potential revenue generation, raising concerns about the company's ability to sustain itself financially in the interim.
FAQ
What is the recent equity award granted by LB Pharmaceuticals?
LB Pharmaceuticals granted Dr. Minako Pazdera an equity award of options to purchase 140,000 shares under its 2025 Equity Incentive Plan.
Who is Dr. Minako Pazdera?
Dr. Minako Pazdera is the newly appointed General Counsel of LB Pharmaceuticals.
What is LB-102?
LB-102 is a novel investigational small molecule intended for treating neuropsychiatric disorders, potentially the first benzamide antipsychotic in the U.S.
What clinical trials is LB-102 currently undergoing?
LB-102 is in a Phase 2 trial for bipolar depression and plans to initiate a Phase 3 trial for schizophrenia in early 2026.
What potential does LB-102 have for neuropsychiatric diseases?
LB-102 may address schizophrenia, bipolar depression, and other conditions with its unique receptor activity and therapeutic profile.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LBRX Insider Trading Activity
$LBRX insiders have traded $LBRX stock on the open market 6 times in the past 6 months. Of those trades, 6 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $LBRX stock by insiders over the last 6 months:
- TRACK BIOTECHNOLOGY MASTER FUND, LTD. DEEP has made 2 purchases buying 2,666,666 shares for an estimated $39,999,990 and 0 sales.
- RAN NUSSBAUM purchased 1,000,000 shares for an estimated $15,000,000
- MANAGEMENT 4 G.P. (2015) LTD. PONTIFAX purchased 1,000,000 shares for an estimated $15,000,000
- VENTURES GP III, L.L.C. VIDA has made 2 purchases buying 333,333 shares for an estimated $4,999,995 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LBRX Hedge Fund Activity
We have seen 61 institutional investors add shares of $LBRX stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 3,352,804 shares (+inf%) to their portfolio in Q3 2025, for an estimated $52,940,775
- RA CAPITAL MANAGEMENT, L.P. added 1,776,958 shares (+inf%) to their portfolio in Q3 2025, for an estimated $28,058,166
- TCG CROSSOVER MANAGEMENT, LLC added 1,745,016 shares (+inf%) to their portfolio in Q3 2025, for an estimated $27,553,802
- COMMODORE CAPITAL LP added 1,500,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $23,685,000
- LOGOS GLOBAL MANAGEMENT LP added 1,130,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $17,842,700
- VANGUARD GROUP INC added 1,112,978 shares (+inf%) to their portfolio in Q4 2025, for an estimated $24,774,890
- JPMORGAN CHASE & CO added 1,032,603 shares (+inf%) to their portfolio in Q3 2025, for an estimated $16,304,801
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LBRX Analyst Ratings
Wall Street analysts have issued reports on $LBRX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 12/11/2025
- Piper Sandler issued a "Overweight" rating on 10/06/2025
- Leerink Partners issued a "Outperform" rating on 10/06/2025
To track analyst ratings and price targets for $LBRX, check out Quiver Quantitative's $LBRX forecast page.
$LBRX Price Targets
Multiple analysts have issued price targets for $LBRX recently. We have seen 3 analysts offer price targets for $LBRX in the last 6 months, with a median target of $35.0.
Here are some recent targets:
- Paul Matteis from Stifel set a target price of $35.0 on 12/11/2025
- Yasmeen Rahimi from Piper Sandler set a target price of $78.0 on 10/06/2025
- Marc Goodman from Leerink Partners set a target price of $34.0 on 10/06/2025
Full Release
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Dr. Minako Pazdera, the new General Counsel of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on February 10, 2026, pursuant to the “inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Dr. Pazdera entering into employment with LB Pharmaceuticals.
Dr. Pazdera received options to purchase 140,000 shares of LB Pharmaceuticals’ common stock. The options carry a ten-year term and an exercise price per share equal to $24.22, which was the closing price of LB Pharmaceuticals’ common stock on the date of grant, and vests over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48 th of the shares vesting monthly thereafter, subject to continuous service through the applicable vesting dates.
About LB-102
LB-102 is a novel, once-daily, orally administered investigational small molecule and potential first benzamide antipsychotic in the U.S. for the treatment of neuropsychiatric disorders. A methylated derivative of amisulpride, a widely used antipsychotics outside the U.S., LB-102 was developed to retain amisulpride’s benefits while addressing its limitations. LB-102 is a potent and selective antagonist of D2, D3, and 5HT7 receptors with few off-target effects and broad therapeutic potential across psychosis and mood disorders. A Phase 2 clinical trial of LB-102 for bipolar depression is ongoing, and the Company expects to initiate a Phase 3 trial of LB-102 for schizophrenia in 1Q 2026, and a Phase 2 clinical trial for the adjunctive treatment of major depressive disorder in early 2027. Additional expansion opportunities for LB-102 include predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as other neuropsychiatric diseases.
About LB Pharmaceuticals
LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Media and Investor Contact
Ellen Rose
[email protected]
